Cargando…

Risk prediction model for cardiovascular diseases in adults initiating pharmacological treatment for attention-deficit/hyperactivity disorder

BACKGROUND: Available prediction models of cardiovascular diseases (CVDs) may not accurately predict outcomes among individuals initiating pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD). OBJECTIVE: To improve the predictive accuracy of traditional CVD risk factors for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dobrosavljevic, Maja, Fazel, Seena, Du Rietz, Ebba, Li, Lin, Zhang, Le, Chang, Zheng, Jernberg, Tomas, Faraone, Stephen V, Jendle, Johan, Chen, Qi, Brikell, Isabell, Larsson, Henrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Pharmacological Treatments
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685689/ https://www.ncbi.nlm.nih.gov/pubmed/36396339 http://dx.doi.org/10.1136/ebmental-2022-300492

Ejemplares similares

Attention-deficit/hyperactivity disorder as a risk factor for dementia and mild cognitive impairment: A population-based register study
por: Dobrosavljevic, Maja, et al.
Publicado: (2021)

Attention-deficit/hyperactivity disorder symptoms and subsequent cardiometabolic disorders in adults: investigating underlying mechanisms using a longitudinal twin study
por: Dobrosavljevic, Maja, et al.
Publicado: (2023)

Attention‐deficit/hyperactivity disorder is associated with increased risk of cardiovascular diseases: A systematic review and meta‐analysis
por: Li, Lin, et al.
Publicado: (2023)

Genetics of attention deficit hyperactivity disorder
por: Faraone, Stephen V., et al.
Publicado: (2018)

The association between polygenic scores for attention‐deficit/hyperactivity disorder and school performance: The role of attention‐deficit/hyperactivity disorder symptoms, polygenic scores for educational attainment, and shared familial factors
por: Jangmo, Andreas, et al.
Publicado: (2021)

Associations between antipsychotics and risk of violent crimes and suicidal behaviour in personality disorder
por: Herttua, Kimmo, et al.
Publicado: (2022)

Cardiovascular risk factors in attention‐deficit/hyperactivity disorder: A family design study of Swedish conscripts
por: Garcia‐Argibay, Miguel, et al.
Publicado: (2022)

Harnessing Twitter data to survey public attention and attitudes towards COVID-19 vaccines in the UK
por: Fazel, Seena, et al.
Publicado: (2021)

Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis
por: Zhang, Le, et al.
Publicado: (2022)

Association of Polygenic Risk for Attention-Deficit/Hyperactivity Disorder With Co-occurring Traits and Disorders
por: Du Rietz, Ebba, et al.
Publicado: (2018)

A Genetic Investigation of Sex Bias in the Prevalence of Attention-Deficit/Hyperactivity Disorder
por: Martin, Joanna, et al.
Publicado: (2018)

Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs With Risk for Attention-Deficit/Hyperactivity Disorder in Offspring
por: Christensen, Jakob, et al.
Publicado: (2019)

Attention-deficit hyperactivity disorder (ADHD) stimulant medications as cognitive enhancers
por: Advokat, Claire, et al.
Publicado: (2013)

Predictive validity of parent- and self-rated ADHD symptoms in adolescence on adverse socioeconomic and health outcomes
por: Du Rietz, Ebba, et al.
Publicado: (2017)

Treating children with attention-deficit/hyperactivity disorder and comorbid epilepsy
por: Kattimani, Shivanand, et al.
Publicado: (2011)

Early life injuries and the development of attention deficit/hyperactivity disorder
por: Wimberley, Theresa, et al.
Publicado: (2022)

Predicting childhood and adolescent attention-deficit/hyperactivity disorder onset: a nationwide deep learning approach
por: Garcia-Argibay, Miguel, et al.
Publicado: (2022)

Phytotherapy for Attention Deficit Hyperactivity Disorder (ADHD): A Systematic Review and Meta-analysis
por: Dutta, Tusheema, et al.
Publicado: (2022)

Network pharmacology, molecular docking, and experimental validation to explore the potential mechanism of Long Mu Qing Xin mixture for the treatment of attention deficit hyperactivity disorder
por: Li, Xuejun, et al.
Publicado: (2023)

Polygenic risk scores and early manifestations of attention‐deficit/hyperactivity disorder
por: Larsson, Henrik, et al.
Publicado: (2022)

Mapping phenotypic and aetiological associations between ADHD and physical conditions in adulthood in Sweden: a genetically informed register study
por: Du Rietz, Ebba, et al.
Publicado: (2021)

Childhood symptoms of attention‐deficit/hyperactivity disorder and borderline personality disorder
por: Tiger, Annika, et al.
Publicado: (2022)

The association between attention-deficit/hyperactivity (ADHD) symptoms and self-employment
por: Verheul, Ingrid, et al.
Publicado: (2016)

The role of ADHD genetic risk in mid-to-late life somatic health conditions
por: Garcia-Argibay, Miguel, et al.
Publicado: (2022)

Correction: The role of ADHD genetic risk in mid-to-late life somatic health conditions
por: Garcia-Argibay, Miguel, et al.
Publicado: (2022)

Common psychiatric and metabolic comorbidity of adult attention-deficit/hyperactivity disorder: A population-based cross-sectional study
por: Chen, Qi, et al.
Publicado: (2018)

Triple Diagnosis of Attention-Deficit/Hyperactivity Disorder with Co-existing Bipolar and Alcohol Use Disorders: Clinical Aspects and Pharmacological Treatments
por: Weiss, Francesco, et al.
Publicado: (2023)

Population Pharmacokinetics of Viloxazine Extended‐Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2021)

The genetics of attention deficit/hyperactivity disorder in adults, a review
por: Franke, B, et al.
Publicado: (2012)

Attention-deficit/hyperactivity disorder and smoking habits in pregnant women
por: Andersson, Anneli, et al.
Publicado: (2020)

Familial co-aggregation of attention-deficit/hyperactivity disorder and autoimmune diseases: a cohort study based on Swedish population-wide registers
por: Hegvik, Tor-Arne, et al.
Publicado: (2021)

Cognitive correlates of attention-deficit hyperactivity disorder in children and adolescents with high intellectual ability
por: Cadenas, María, et al.
Publicado: (2020)

Association Between Pharmacological Treatment of Attention-Deficit/Hyperactivity Disorder and Long-term Unemployment Among Working-Age Individuals in Sweden
por: Li, Lin, et al.
Publicado: (2022)

Pharmacological Treatment of Attention Deficit Hyperactivity Disorder in Children and Adolescents: Clinical Strategies
por: Shier, Anna C., et al.
Publicado: (2012)

Global Mental Health and Pharmacology: The Case of Attention Deficit and Hyperactivity Disorders in Brazil
por: Ortega, Francisco, et al.
Publicado: (2020)

A review of Cochrane reviews on pharmacological treatment for attention deficit hyperactivity disorder
por: Santos, Giovanna Marcílio, et al.
Publicado: (2021)

Pain hypersensitivity in a pharmacological mouse model of attention-deficit/hyperactivity disorder
por: Bouchatta, Otmane, et al.
Publicado: (2022)

Exome chip analyses in adult attention deficit hyperactivity disorder
por: Zayats, T, et al.
Publicado: (2016)

Attention-deficit hyperactivity disorder in adults: A systematic review and meta-analysis of genetic, pharmacogenetic and biochemical studies
por: Bonvicini, C, et al.
Publicado: (2016)

An Shen Ding Zhi Ling Alleviates Symptoms of Attention Deficit Hyperactivity Disorder via Anti-Inflammatory Effects in Spontaneous Hypertensive Rats
por: Song, Yuchen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b1in8c3tggfid4f5p8kn2osq2h